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Abstract Chronic obstructive pulmonary disease (COPD) is an obstructive lung disorder characterized by progressive 
airFlow limitation that is not reversible or only partially reversible, including chronic bronchitis and emphysema. Confronting 
COPD in North America and Europe was the first large-scale international survey to attempt to quantify the country-specific 
burden of the disease, collecting data on clinical outcomes, healthcare resource utilization, and lost productivity, from 
patients and physicians in France and seven other countriesThe economic analysis of the French survey results showed 
that patients with COPD required considerable utilization of healthcare resources, with annual direct costs estimated at 
630 per patient. In addition, COPD-related illness or disability prevented many patients from working, with an estimated 
annual indirect cost of E IO78 per patient. 
The survey suggested underdiagnosis and undertreatment of COPD by healthcare professionals, and patients reported 
poor symptom control.The cost of unscheduled care (E I5 I) was almost double the cost of scheduled visits to healthcare 
professionals (E82). This suggests that improving the long-term management of chronic symptoms by healthcare 
professionals could reduce the burden of disease. As in other countries, the clinical management of COPD in France may 
be improved by following guideline recommendations for COPD treatment.These include smoking cessation at all stages 
of the disease, regular treatment of chronic symptoms with bronchodilators in dyspnoeic patients, and pulmonary 
rehabilitation.The results of the survey also showed that the societal cost of COPD was considerably greater in patients 
with severe disease (e2882) compared with mild COPD (8289).This suggests that interventions that could help delay 
the progression of COPD to the advanced stages of the disease (such as smoking cessation) could be of economic benefit, 
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is an 
obstructive lung disorder characterized by progressive 
airflow limitation that is not reversible or only partially 
reversible, including chronic bronchitis and emphysema. 
The development of COPD is strongly linked to a long- 
term history of smoking behaviour (I).The disease affects 
an estimated 44 million people worldwide, and is 
associated with considerable morbidity and mortality (2). 
In France, COPD is known to cause 10000-I 2000 
deaths each year (3), but epidemiological data on the 
disease is limited. In the late 1970s the prevalence of 
chronic bronchitis was estimated at around 5%, on the 
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basis of the presence of respiratory symptoms in people 
who were current smokers (4). A recent postal survey 
conducted from I998 to I999 in a representative sample 
of over 14000 people from the adult population 
(225years), assessed the proportion of patients with 
chronic bronchitis as defined by persistent cough and 
sputum production for at least 3 months in the previous 
2 years (5).The overall prevalence of chronic bronchitis 
in the adult population (225 years) was estimated at 
4. I %  (equivalent to I .7 million people). Increased 
prevalence rates were associated with smoking 
behaviour (22% in patients who smoked over 
20 cigarettes per day) and comorbidity. 
In addition to prevalence, the survey assessed patient 
perceptions of the diagnosis and management of their 
self-reported respiratory symptoms. The results 
suggested that chronic bronchitis was probably 
underdiagnosed and under-treated in France: 76% of 
respondents with symptoms of the disease reported that 
they had not received a diagnosis from their primary 
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care practitioner, and only 7% of patients without 
comorbidities were receiving treatment that they 
thought was related to their respiratory symptoms (5). 
Diagnosis and treatment rates were higher in individuals 
reporting a history of, or symptoms consistent with, 
comorbid illnesses (such as pulmonary tuberculosis, 
bronchiectasis or heart failure) compared with patients 
without comorbidities (52% and 38% of patients 
respectively). The insufficient attention given to 
symptoms of chronic bronchitis among both patients and 
physicians, and the absence of screening programmes for 
COPD were put forward by the study investigators as 
reasons for the underdiagnosis and subsequent 
undertreatment of this disease (5). 
National and international treatment guidelines 
highlight the importance of early diagnosis and treatment 
to reduce the morbidity associated with COPD (l,6). 
Available data suggests that COPD has a significant 
impact on the healthcare system in France: the disease 
accounts for over 260000 primary consultations per 
year (7) and is the ninth leading cause of hospitalization 
(8). Much of the burden of COPD on secondary care 
may be due to acute exacerbations of the disease, as 
shown by a prospective survey of the cost of recurrent 
respiratory infections in 244 patients with COPD (7). 
The direct cost per acute exacerbation was estimated at 
3289 francs (1994 values; e5Ol), of which 60% was 
accounted for by hospital treatment. In addition to direct 
costs, acute exacerbations of COPD in this study 
resulted in indirect costs of up to 4429 francs (8675) 
per patient, due to patient absence from work (mean 
IO.4 days of work lost per patient). 
A descriptive cost-of-illness study conducted recently 
in France has demonstrated the high economic burden 
of COPD on the healthcare system in this country (9). 
Primary care practitioners and respiratory specialists 
collected data on symptoms (exacerbation frequency) 
and healthcare resource utilization (including visits to 
healthcare professionals, laboratory tests, drug 
treatment, hospitalizations, rehabilitation and other care 
services) in patients with COPD (>45 years of age, 
n=255) over a I -year period. Three-quarters (77%) of 
patients had at least one exacerbation of COPD (mean 
I .7 exacerbations per patient). The direct per patient 
cost of COPD amounted to an estimated e4366 per 
patient, and the main cost drivers were hospitalizations 
(including inpatient physician services, accounting for 
36% of costs) and medication use (3 I %  of costs). The 
cost of COPD to the healthcare system increased with 
the severity of disease: patients with severe COPD (FEV, 
135% of normal predicted value [FEV, :forced expiratory 
flow in I second]) were associated with an estimated 
direct per patient cost of e7502, compared with c38 I3 
for patients with moderately severe COPD (FEV, 
36-50% predicted) and 83697 for patients with 
moderate COPD (FEV, 5 l-80% predicted) (9). 
Obtaining data on the impact of COPD on the patient, 
healthcare system and the economy may help to raise 
awareness of the disease among physicians and the 
general population, and highlight the need for improved 
treatment of the disease in France. Confronting COP/I in 
North America and Europe was the first large-scale 
international survey to attempt to quantify the country- 
specific burden of the disease, collecting data on clinical 
outcomes, healthcare resource utilization, and lost 
productivity, from patients and physicians in France and 
six other countries. Patients with COPD reported 
experiencing frequent and disabling symptoms, which 
had a considerable impact on their quality of life (I 0). 
Direct and indirect costs were calculated from the 
survey data, to estimate the economic impact of COPD 
in each country.This paper presents the results of the 
health economic analysis of the French survey. 
METHODS 
Survey details 
The Confronting COPD survey used random digit 
dialling of telephone numbers to systematically screen 
geographically stratified samples of 201 921 households 
in France and seven other countries (Canada, Germany, 
Italy, the Netherlands, Spain, the U.K. and the U.S.A.). 
Telephone interviews were used to collect information 
on clinical outcomes, healthcare resource use and lost 
productivity. Patients included in the survey (n=3265) 
reported that they had been diagnosed with COPD, 
chronic bronchitis or emphysema by a physician, or had 
symptoms consistent with a diagnosis of chronic 
bronchitis (persistent cough with sputum production for 
at least 2 years) ( I O).The economic analysis of the survey 
was conducted on data from all these patient groups. 
Therefore, the term ‘COPD’ in this paper refers 
collectively to patients with physician diagnosed COPD, 
chronic bronchitis or emphysema, and patients reporting 
symptoms of chronic bronchitis. Direct, indirect and total 
societal costs per patient were calculated for the survey 
sample from each country, and a sub-analysis was 
conducted for patient groups stratified by disease 
severity (based on patient self-report, and calculated 
from scores on the Medical Research Council (MRC) 
Dyspnoea Scale: mild=@2, moderate=34, severe=5), 
sex, smoking status, comorbidity and education level. 
Further details on the methodology used in the 
economic analysis are reported elsewhere (I I). 
Cost calculations 
The majority of the unit costs for healthcare resource 
use and lost productivity for the French sample from the 
Confronting COPD survey (Table I) were derived from 
local public databases. Unit costs for visits to healthcare 
professionals and laboratory tests were derived from the 
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Health Insurance System (2001), and unit costs for 
hospitalization were sourced from the Programme de 
Medicalisotion des Sys3mes d’lnfbrmation ( I999).The unit 
cost of a chest X-ray, electrocardiogram (ECG), or 
computerized tomography (CT) scan during an inpatient 
hospitalization was included in the unit cost of a hospital 
stay. Data from the lnstitut National de la Statistique et des 
Etudes Economiques (I 999) provided the unit cost per day 
of work loss. 
The mean annual cost for each prescription drug class 
was calculated by applying unit costs to data from the 
United Kingdom Mediplus database (mean number of 
packs per year and the strengths and formulations of 
medications dispensed in patients with COPD), weighted 
for average level of use. Although the legal age of 
retirement in France is 60 years for both men and 
women, unit costs for lost productivity were applied to 
patients below the age of 65 years, to allow comparison 
with the indirect cost data of other countries in the 
survey, all of which have mean retirement ages of 
65 years or below ( 12-l 7). 
RESULTS 
Patient demographics 
The demographics and clinical characteristics of the 400 
patients enrolled in the French sample of the survey are 
summarized in Table 2. Patients ranged from 45 to 92 years 
of age, and 30% of the patients were female.The sample 
was almost equally divided between former and current 
smokers, with a mean pack-year smoking history of 
38 pack-years (maximum I65 pack years). A diagnosis of 
chronic bronchitis was reported by 50% of patients, 17% of 
the patients had been diagnosed with emphysema, and I 6% 
of the patients had been diagnosed with COPD. Despite 
describing symptoms of chronic bronchitis (persistent 
cough with sputum production for at least 2 years prior to 
the survey), 17% of patients reported that they had not 
been diagnosed with COPD. Severe COPD was reported 
by 24% of patients, and 20% of patients thought that their 
condition was poorly controlled, or not at all controlled, 
with current treatment. One-third of patients reported 
other serious or chronic health conditions, most 
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FIGURE I. Percentage of patlents reporting healthcare resource use/contacts during the I2 months prior to the survey. PCP: Primary 
care practitioner 
commonly kidney problems (I 4% of patients), diabetes 
(So/,), heart disease (5%), or hypertension (5%). 
Healthcare resource utilization 
In the French survey sample, 76% of patients reported 
that they usually went to their primary care practitioner 
(PCP) for the management of their respiratory 
condition. Almost 2000 PCP visits were reported by 
survey respondents, with 17% of patients reporting 
unscheduled visits (Fig. I, Table 3). Specialist care was 
reported by 25% of the patients (including 14% under 
the care of a respiratory specialist, with the remaining 
patients visiting a specialist of internal medicine, 
cardiology, allergy or other discipline), with an estimated 
total of 469 specialist visits, most of which were 
reported as unscheduled or scheduled visits (Table 3). 
Although only I5 patients (4% of the sample) had an 
unscheduled specialist visit in the previous year, over IO0 
visits were recorded, equivalent to a mean of seven 
specialist visits per patient reporting this type of 
healthcare professional contact. 
At some time in their lives, 22% of patients in the French 
survey sample reported that they had been hospitalized 
for a reason they thought to be COPD, with I I% of 
patients reporting an inpatient stay in the l2-month 
period prior to the survey (Fig. l).The total number of 
hospitalizations reported in the previous year was 135 
(Table 3), with a mean of 0.34 hospitalizations per patient. 
Emergency room visits for the treatment of presumed 
COPD were reported by 9% of patients, with a maximum 
of five visits by any one patient during the previous year. 
The use of regular prescribed medication that was 
thought to be for COPD was reported by 5 I %  of the 
patients in the French survey sample. The three main 
classes of drug prescribed were inhaled corticosteroids, 
short-acting P,-agonists and long-acting &-agonists 
(Fig. 2).A minority of patients (I 4.5%) had a nebulizer to 
administer bronchodilator drugs. 
Figure 3 summarizes the reported use of other 
treatments received by the patients, and considered by 
them to be related to COPD. In the previous year, 5 I %  
of the patients surveyed had received an influenza 
vaccination. A similar proportion of patients had 
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FIGURE 2. Use of regular prescribed medication in the survey sample. 
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FIGURE 3. Influenza vaccinations. antibiotics and use of home oxygen therapy reported by the survey sample 
received a course of antibiotics for the treatment of 
respiratory infections (mean I .09 courses per patient, 
SD 4.27). Home oxygen therapy was used by 9% of 
patients in the survey (n=34), with almost 7400 days of 
use in the last I2 months (equivalent to a mean of 2 I7 
days use per patient reporting oxygen therapy). The 
mean number of days of oxygen use for the survey 
sample was 18.46 per patient (SD 77.69; minimum 
0 days, maximum 365 days). 
Data on laboratory tests were also collected by the 
Confronting COPD survey. Over 700 tests were 
reported by patients in France (mean I .78 tests per 
patient), as summarized in Table 4. The most commonly 
reported tests were chest X-rays and ECGs (reported 
by 47% and 4 I % of patients respectively). 
Although not included in the economic analysis, the 
survey also assessed how many patients had ever had 
their lung function tested by a healthcare professional: 
70% of patients in the French sample had undergone 
pulmonary function tests (either peak flow testing or 
spirometry) (I 8). 
Lost productivity 
Around half (48%) of the patients in the French arm of the 
Confronting COPD survey were in employment. During 
the I2 months prior to the survey, I I % of patients (n=44) 
reported that they were prevented from working 
altogether, 4% of patients (n= 14) estimated that they were 
limited in the work that they were able to undertake, and 
a further 4% of patients (n= 16) reported a period of 
absence from work that they thought was related to 
C0PD.A total of 3 I54 days of work were lost during the 
IZmonth period prior to the survey, with a mean of 
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7.89 days lost per patient (SD 39.79, maximum 365 days was estimated at ‘El 15 per patient. Inpatient 
lost). A small proportion (3%) of patients reported hospitalizations were a major cost driver, accounting for 
caregiver work loss, with 45 days lost in the past year. over one-fifth (22%) of direct costs (e I I8 per patient) 
(Fig. 4). When the cost of emergency room visits and 
Direct costs unscheduled PCP contacts were added to the cost of 
hospitalizations, the estimated cost of unscheduled 
The estimated annual direct per patient cost of COPD in 
the French sample was e530 (Table 5). Oxygen therapy 
was associated with the highest annual cost of any 
individual resource measure, at a cost of E I33 per patient 
(equivalent to 50% of treatment costs and 25% of direct 
costs).The annual cost of regular prescription medication 
treatment totalled e I5 I per patient: 28% of the estimated 
annual cost of COPD to the healthcare system. In 
contrast, scheduled PCP and specialist visits accounted for 
just 15% of direct per patient costs for the survey sample 
(Fig. 4).The per patient cost of laboratory tests that were 
thought to be related to COPD was estimated at +E3 I. 
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FIGURE 4. Percentage breakdown of annual direct costs of COPD for the French sample. PCP: Primary care practitioner 
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FIGURE 5. Societal costs of COPD by disease severity 
Indirect and total societal costs Costs sub-analysis 
The cost of work loss in patients with diagnosed or A sub-analysis was conducted to see if there was any 
undiagnosed COPD was added to the direct costs of the relationship between the direct, indirect and societal 
disease, to gain an estimate of the annual societal cost of costs of COPD and disease severity.The proportion of 
COPD per patient. Patient productivity loss cost an patients with mild, moderate or severe COPD was based 
estimated e 1078, bringing the societal cost to ‘2 1608 on patient self-report, and calculated from scores on the 
per patient in the French sample. Medical Research Council (MRC) Dyspnoea Scale (mild: 
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O-2, moderate: 3-I, severe: 5).The results for the French 
sample revealed that, using either assessment method, 
patients with severe COPD were considerably more 
costly to the healthcare system, the economy and society 
as a whole than patients with moderate or mild disease 
(Fig. 5). 
Costs were also assessed in relation to patient sex, 
smoking status, comorbidity and education level. Direct 
costs were higher in males than females, former smokers 
than current smokers, patients with comorbidity 
compared with no comorbidity, and patients who were 
not educated beyond basic schooling compared with 
patients who did receive further education (Table 6). 
However, indirect and societal costs were higher in 
females than in males, and in current smokers compared 
with former smokers. 
DISCUSSION 
The Confronting COPD survey was one of the first 
studies conducted in France to quantify healthcare 
resource use, lost productivity, direct costs and indirect 
costs associated with the disease. Patients included in the 
survey had been diagnosed with COPD, chronic 
bronchitis and emphysema, or had symptoms suggestive 
of chronic bronchitis (persistent cough with sputum 
production for the past 2years) without previous 
diagnosis of this condition. 
In France, the results of the survey showed that 
patients who reported diagnosed or undiagnosed COPD 
required considerable utilization of healthcare resources, 
with annual direct costs estimated at G30 per patient. 
Supporting the results of a previous cost-of-illness study 
conducted in this country (9), treatment for COPD and 
inpatient hospitalizations were key drivers of direct 
costs. The current survey also suggested that COPD 
prevented many patients from working, with over 3 150 
days work lost at an estimated annual cost of e IO78 per 
patient.The indirect cost of COPD therefore accounted 
for 67% of the estimated societal of the disease (e I608 
per patient). As indirect costs calculation did not include 
the cost of caregiver work loss, it is likely that the real 
economic impact of COPD may have been 
underestimated by this survey. 
As in other countries (l2-l7), the results of the 
analysis of French data from the Confronting COPD 
survey suggest that reducing morbidity from COPD 
should be a high priority for alleviating the burden of 
this disease. Around one in six patients who had 
symptoms consistent with chronic bronchitis had not 
been diagnosed, supporting the results of a previous 
study that showed patients with this condition were 
often going undetected in France (5). In addition to 
underdiagnosis, the survey suggested that COPD 
(including chronic bronchitis and emphysema) was 
undertreated. Only half (5 I %) of the patients reported 
that they were currently being treated with regular 
prescribed medications. A diagnosis of COPD, chronic 
bronchitis or emphysema was reported by 83% of 
patients: therefore, assuming that all undiagnosed 
patients remained untreated, this suggests that almost 
one-third (32%) of patients diagnosed with these 
conditions were not receiving any regular treatment for 
chronic respiratory symptoms. 
The undertreatment of COPD in France may be due, 
at least in part, to uncertainty among physicians about 
which medications are likely to be most effective in the 
management of the disease. National recommendations 
for the management of COPD, which were produced by 
the So&@ de Pneumologie de Longue Francaise (SPLF) in 
1997, are in the process of being updated (I 9).A national 
programme has recently been put into place by the SPLF 
to improve the way COPD is managed by healthcare 
professionals (20), although the benefits of this 
programme may not be seen for some time. 
The sub-optimal treatment of COPD may lead to poor 
symptom control, and increase the frequency and severity 
of acute exacerbations of the disease. One-fifth of patients 
in the survey sample felt that their condition was poorly 
or not at all controlled at the time of the survey, and 
almost half of patients reported receiving antibiotics for 
respiratory infections, suggesting that a considerable 
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number of COPD exacerbations were experienced. The 
extent of unscheduled care visits (inpatient 
hospitalizations, emergency room visits, contacts with 
primary care practitioners or specialists),which accounted 
for 28% of the total direct costs of the disease, may be 
taken as an index of inadequate symptom control. The 
cost of unscheduled care (E I5 I) was almost double the 
cost of scheduled visits to healthcare professionals (E82). 
This suggests that a shift away from acute emergency 
treatment towards improving the long-term management 
of chronic symptoms by healthcare professionals could 
reduce the burden of the disease in this country. 
As in other countries, the clinical management of 
COPD in France may be improved by following guideline 
recommendations for COPD treatment. These include 
smoking cessation at all stages of the disease, regular 
treatment of chronic symptoms with bronchodilators in 
dyspnoeic patients, and pulmonary rehabilitation (I). 
With the aim of preventing exacerbations caused by 
respiratory infection, treatment guidelines also 
recommend influenza vaccination for all patients 
diagnosed with COPD (I). However, the current survey 
showed that only 5 I % of patients in the French sample 
had received an influenza vaccination in the previous 
year.Therefore, it is possible that improved coverage of 
the COPD population by influenza vaccination could 
help to reduce the impact of this disease on both the 
patient and the healthcare system in France. 
The sub-analysis of direct costs calculated in the survey 
showed that the average cost of treating a patient who 
reported a score of 5 (severe dyspnoea) on the MRC 
Dyspnoea Scale was over eight times higher than the cost 
of treating a patient who reported a score of O-2 (mild 
dyspnoea).The high cost of treating patients with severe 
dyspnoea may have been related to the use of home 
oxygen therapy, which was reported by only 9% of 
patients in the survey, but accounted for 25% of the total 
direct costs of the disease. However, data specifically 
pertaining to the subgroup of patients under oxygen 
therapy in this survey are not availab1e.A previous study 
suggested that inappropriate prescriptions may be 
contributing to the high costs of home oxygen therapy in 
France, with many patients receiving therapy although 
they did not meet prescription guideline criteria (i.e. a 
severe degree of hypoxaemia) (21). This suggests that 
improving physician guidance on the use of home oxygen 
treatment could reduce the direct costs of COPD 
treatment in this country. 
In addition to direct costs, the results of the current 
survey also showed that the indirect and total societal 
costs of COPD were considerably greater in patients 
with severe disease compared with mild COPD, 
supporting a previous cost-of-illness study conducted in 
France (9).These results suggest that interventions that 
could help delay the progression of COPD to the 
advanced stages of the disease could be of economic 
benefit. Smoking cessation is the only intervention 
proven to delay the decline in lung function in patients 
with COPD (I). Of course, the success of such 
interventions depends on the effective education of 
smokers, in order to promote early contact with a 
healthcare professional and, above all, on the effective 
education of general practitioners, in order to optimize 
the early recognition of the disease. Although this is not 
currently being achieved in France, improving the early 
recognition of COPD is a key target of major respiratory 
disease organizations, such as the SPLF and the Comite 
National de Lutte come les Maladies Respirotoires. 
The sub-analysis of costs also showed that former 
smokers were more costly to society than current 
smokers with COPD.This may be because patients may 
be more likely to stop smoking when they are 
experiencing symptoms of COPD (i.e. they have more 
severe disease than current smokers). Further analysis of 
the survey data would be required to confirm this. In 
addition, patients with comorbid conditions had higher 
direct and indirect costs than patients without 
comorbidities.This is probably due to greater ill health 
(and therefore greater healthcare resource use and lost 
productivity) in patients with other serious health 
conditions (such as cancer or coronary heart disease) 
than in patients diagnosed with COPD alone. The 
particularly high costs associated with comorbidity in 
patients with COPD have been reported in separate 
studies (22-23). 
The methodology used in the Confronting COPD 
survey has strengths and limitations. The survey used 
randomized digit dialling and stratified sampling methods 
to obtain a national sample of patients from the general 
population.As more than 94% of households in France 
have at least one telephone line (24) population 
coverage was high.Alternative survey methods may be 
more likely to exclude patients with COPD (for 
example, using primary care practice registers would 
omit patients who remain undiagnosed, while using 
specialist referral or lung function criteria may lead to 
the inclusion of disproportionately high numbers of 
patients with relatively severe disease). However, the 
survey relied on self-report to identify patients with a 
diagnosis of COPD, chronic bronchitis or emphysema, or 
symptoms consistent with chronic bronchitis, as the 
presence of obstructive lung disease could not be 
confirmed with spirometry. To increase the likelihood 
that the patients included in the survey did have COPD, 
all participants were aged 45 years or older and were 
current or former smokers, with at least a IO pack-year 
smoking history (with the rationale that COPD develops 
in middle-age, most commonly following a long-term 
history of smoking behaviour). Patients who reported a 
diagnosis of asthma were excluded from taking part in 
the survey. Although it is possible that some of the 
patients who reported a diagnosis of COPD may also 
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have had asthma, this is disputed by differences between 
the clinical results of the current survey (e.g. in terms of 
symptoms and disability levels) and those of an 
international asthma survey that used similar 
methodology (I 0,25). 
CONCLUSION 
COPD has a significant impact on the healthcare system 
and society in France.The economic impact of the disease 
may be reduced by improving the management of COPD 
in primary care, as the disease is currently underdiagnosed 
and undertreated. Interventions aimed at improving 
symptoms, preventing exacerbations and delaying the 
progression of disease could play an important role in 
reducing the impact of COPD in France. 
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